A case of hepatitis C-related cirrhosis that developed cancer of unknown primary origin and followed with fulminant course after treatment with direct-acting antivirals-Reference-Cited by-同舟云学术

A case of hepatitis C-related cirrhosis that developed cancer of unknown primary origin and followed with fulminant course after treatment with direct-acting antivirals

Published:2022-02-01 Issue:2 Volume:63 Page:77-86
ISSN:0451-4203
Container-title:Kanzo
language:en
Short-container-title:Acta hepatologica Japonica

Author:

Tajima Kazuaki¹,Fukushima Nobuyoshi¹,Kira Keishi²,Togo Masaaki¹,Shibata Masashi¹,Mawatari Shogo¹,Hayashi Hiroko³,Shimokawa Isao³,Takeshima Fuminao¹,Nakao Kazuhiko²

Affiliation:

1. Department of Internal Medicine, Nagasaki Prefecture Gotochuoh Hospital

2. Department of Gastroenterology and Heptology, Nagasaki University Graduate School of Biomedical Sciences

3. Department of Pathology, Nagasaki University Graduate School of Biomedical Science

Publisher

Japan Society of Hepatology

Subject

Hepatology

Link

https://www.jstage.jst.go.jp/article/kanzo/63/2/63_77/_pdf

Reference34 articles.

1. 1) Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol 2016; 65: 727-733

2. 2) Reig M, Marino Z, Perello C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016; 65: 719-726

3. 3) Kanda T, Matsuoka S, Moriyama M, et al. Early occurrence and recurrence of hepatocellular carcinoma in hepatitis C virus-infected patients after sustained virological response. Hepatol Int 2018; 12: 90-93

4. 4) ANRS collaborative study group on hepatocellular carcinoma. Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol 2016; 65: 734-740

5. 5) Ioannou GN, Green PK, Berry K. HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma. J Hepatol 2018; 68: 25-32

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multiple drugs;Reactions Weekly;2022-11-26